MedTrace Logo

Periodontal Status and Endothelial Dysfunction in Patients With Polycystic Ovary Syndrome

NCT06184412 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-01-09

No results posted yet for this study

Summary

Emerging research indicates a link between polycystic ovary syndrome (PCOS) and periodontal diseases, revealing the intricate relationship between oral health and systemic conditions. PCOS, a hormonal disorder in women of reproductive age, often associates with obesity, dyslipidemia, and insulin resistance, heightening the risk for type 2 diabetes (T2D) and cardiovascular disease (CVD). The pathogenesis of PCOS involves an inflammatory response marked by increased CRP, inflammatory cytokines, elevated blood leukocytes, adhesion molecule expression, and oxidative stress markers like myeloperoxidase (MPO).

Periodontal diseases, bacterial infections affecting gums, ligaments, cement, and bone, include gingivitis (gum inflammation) and periodontitis (irreversible tissue destruction). Evidence suggests a link between periodontitis and increased CVD risk, while such association with gingivitis is limited.

Potential mechanisms linking periodontal diseases and CVD involve cytokine release, oral bacteria toxin production, and direct bloodstream transfer. Recognition of lipopolysaccharide (LPS) and TNFα triggers innate immune cells via TLR4 and TNFR, activating NF-κB and JNK expression. JNK amplifies inflammatory responses, inducing proinflammatory genes, and TNFα, IL-1, IL-6, and IL-8 can invade endothelial layers, promoting adhesion molecule expression. Enhanced leukocyte ROS production, especially in periodontitis, contributes to endothelial dysfunction and heightened cardiovascular risk.

The activation of multiple inflammatory pathways likely links PCOS, periodontal disease, and increased cardiovascular risk. Thus, the researchers aim to investigate if the presence of periodontal diseases, particularly gingivitis, exacerbates oxidative stress, inflammation and atherosclerosis surrogate markers in women with PCOS, and explore the underlying molecular mechanisms.

Conditions

  • Periodontal Diseases

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

    lead OTHER

Principal Investigators

  • Milagros Rocha, PhD · FISABIO-HOSPITAL DR PESET

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-06-01
Completion
2022-09-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06184412 on ClinicalTrials.gov